Navigation Links
Pharmasset Initiates Exploratory Interferon Sparing Clinical Trial of PSI-7977 for Chronic Hepatitis C
Date:12/14/2010

PRINCETON, N.J., Dec. 14, 2010 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that dosing has begun in an exploratory study of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 400mg QD in combination with ribavirin (RBV), with 0, 4, 8, or 12 weeks of pegylated interferon alfa 2a (Peg-IFN) in treatment-naive patients infected with HCV genotype 2 or 3.

"Based on the encouraging efficacy, safety and resistance data from the Phase 2a trial with PSI-7977 in combination with pegylated interferon and ribavirin, we initiated a study to explore shorter durations of interferon, including an interferon-free regimen in treatment naïve patients with HCV genotype 2 or 3," stated Michelle Berrey, MD, MPH, Pharmasset's Chief Medical Officer. "An important limitation to the current treatment of HCV patients is the use of interferon with its associated side effect profile. We believe that PSI-7977's high barrier to resistance and the lack of a significant effect of IL28B genotype in the Phase 2a trial provide us an opportunity with PSI-7977 to explore shorter durations of interferon, and potentially even removing it from the treatment regimen altogether."

About the TrialThe trial is anticipated to enroll approximately 40 patients infected with HCV genotype 2 or 3 who have not previously been treated. The primary endpoint of the trial will be the assessment of safety and tolerability of PSI-7977 400mg QD and RBV for 12 weeks, administered with or without pegylated interferon (Peg-IFN) in treatment naïve patients with HCV genotypes 2 or 3. The trial will be conducted in New Zealand. Patients will be randomized into one of 4 arms:

-- PSI-7977 400mg QD in combination with RBV for 12 weeks (no interferon);

-- PSI-7977 400mg QD in combination with RBV for 12 weeks, with only 4 weeks of Peg-IFN;

-- PSI-7977 400mg QD in combination with RBV for 12 weeks, with only 8 weeks of Peg-IFN;

-- PSI-7977 400mg QD in combination with Peg-IFN and RBV for 12 weeks.

Patients will be stratified by HCV genotype and IL28B status to ensure balance across cohorts.

Pharmasset anticipates reporting interim data from this trial in the first half of 2011.

About Pharmasset Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have four clinical-stage product candidates. RG7128, a cytosine nucleoside analog for chronic HCV infection, is in two Phase 2b clinical studies in combination with Pegasys(R) plus Copegus(R) and is also in the INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys(R) and Copegus(R) to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage HCV candidates include PSI-7977, an unpartnered uracil nucleotide analog that has recently initiated dosing in a Phase 2b study in patients with HCV genotypes 1, 2, or 3, and PSI-938, an unpartnered guanosine nucleotide analog which recently completed a 7-day monotherapy study. We also have in our pipeline an additional purine nucleotide analog, PSI-661, in advanced preclinical development.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:  Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation,  the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates,  the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized.  For a discussion of risks, uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2010 filed with the Securities and Exchange Commission and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission.ContactRichard E. T. Smith, Ph.D.VP, Investor Relations and Corporate CommunicationsOffice +1 (609) 613-4181
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... -- , Isansys  Lifecare, a new generation digital ... wireless patient monitoring platform, as it ships more systems to ... , Scotland and Norway ... system, launched earlier this year, is now being used in ... This new technology significantly enhances the user experience and ...
(Date:5/30/2016)... 2016 According to a ... Market by Type (Stability, Raw Materials, Method Validation, ... (Pharmaceutical Companies, Medical Device Companies) - Global Forecast ... healthy growth during the last decade and is ... between 2016 and 2021 to reach USD 4.13 ...
(Date:5/30/2016)... , May 30, 2016 Eye expert ... of premature babies to seek an eye examination ... condition     Moorfields Eye Hospital Dubai, ... London , has identified premature babies as a ... because of their particular vulnerability to retinopathy of prematurity (ROP). ROP ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... , ... Dr. Charles A. Ditta attained his Doctor of Medical Dentistry Degree ... 1986, where he graduated in the top ten percentile of his class. Dr. Ditta ... He has been a member in good standing for thirty years in the American ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... on patients with cancer, has added Cancer and Careers to its ... more timely content on continuing successful careers while fighting cancer. , As partners, ...
(Date:5/30/2016)... ... May 30, 2016 , ... ... inside of FCPX," said Christina Austin - CEO of Pixel Film Studios. ... within Final Cut Pro X. Choose from abstract transitions to more simple wipes ...
(Date:5/30/2016)... Texas (PRWEB) , ... May 30, 2016 , ... Another ... 7 am in Plano, located at 3960 Legacy Drive, Plano, TX and is open ... Plano Chamber of Commerce followed by a medical open house. The Jasper High School ...
(Date:5/29/2016)... Viejo, CA (PRWEB) , ... May 29, 2016 , ... ... Volume 3 let's the user control the style of their project," said Christina Austin ... set of 30 self-animating web-themed intros created exclusively for use in Final Cut Pro ...
Breaking Medicine News(10 mins):